RESUMEN
Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.
Asunto(s)
Miofibroma , Miofibromatosis , Niño , Monitoreo de Drogas , Humanos , Lactante , Recién Nacido , Miofibroma/tratamiento farmacológico , VinblastinaAsunto(s)
Miofibroma/genética , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/genética , Esclerodermia Localizada/complicaciones , Administración Oral , Adulto , Biopsia/métodos , Enfermedades del Tejido Conjuntivo/patología , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/uso terapéutico , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Humanos , Metotrexato/administración & dosificación , Metotrexato/uso terapéutico , Mutación , Miofibroma/complicaciones , Miofibroma/diagnóstico , Miofibroma/tratamiento farmacológico , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/tratamiento farmacológico , Neoplasias Cutáneas/patología , Resultado del TratamientoRESUMEN
Inflammatory myofibroblastic tumor (IMT) of lung is a rare tumor, accounting for ~0.7% of all lung tumors with varied clinical and radiological presentations. The origin of this tumor is unknown but some studies suggest that it might be a true neoplasm as some mutations on chromosome 2p23 of anaplastic lymphoma kinase (ALK) have been found to be related to this tumor. The morphology of IMT is quite vague and the histopathological diagnosis is predominantly given on excision specimens; in fact, only 6.3% of cases are diagnosed based on analysis of biopsy specimens alone. We illustrate a case of IMT diagnosed in a young male on core biopsy, where the case presented with a large tumor in the lung with metastases to multiple sites that was hence unresectable. Post 3 months of treatment with Crizotinib, there was significant reduction in the tumor size. Another interesting finding was that the ALK immunostain, which helped immensely in the diagnosis, was appreciated better on the Ventana platform rather than on the Dako platform.
Asunto(s)
Quinasa de Linfoma Anaplásico/análisis , Neoplasias Pulmonares/diagnóstico , Miofibroma/diagnóstico , Adulto , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/análisis , Biopsia con Aguja Gruesa , Crizotinib/uso terapéutico , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/patología , Masculino , Miofibroma/tratamiento farmacológico , Miofibroma/patologíaRESUMEN
OBJECTIVES: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor and is prevalent among children and adolescents. In recent years, following the emergence of high-throughput sequencing techniques, rearrangements in genes, such as ALK, ROS1, NTRK, RET, and PDGFRß, have been detected in a considerable proportion of IMT patients. However, the practice of targeted therapy for those patients remains extremely limited. In this study, we report about a 14-year-old boy diagnosed with pulmonary IMT with a mass measuring 12 × 8 cm in the right lower lobe. MATERIALS AND METHODS: Immunohistochemistry (IHC) assay and comprehensive next-generation sequencing (NGS) were performed on the biopsied tumor tissue. RESULTS: The IHC assay revealed an ALK-negative tumor, while NGS detected aTFG-ROS1 rearrangement. The patient achieved continuous remission after treatment with crizotinib (250 mg, bid). CONCLUSION: This case broadens the experience regarding targeted therapy forROS1-rearranged IMT and supports the use of broad molecular profiling testing for optimizing therapeutic options.
Asunto(s)
Crizotinib/uso terapéutico , Reordenamiento Génico , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/genética , Miofibroma/tratamiento farmacológico , Miofibroma/genética , Proteínas Tirosina Quinasas/genética , Proteínas Proto-Oncogénicas/genética , Adolescente , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Biopsia , Crizotinib/administración & dosificación , Crizotinib/efectos adversos , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/diagnóstico , Masculino , Miofibroma/diagnóstico , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/uso terapéutico , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK). Eligible participants were patients aged at least 15 years with a local diagnosis of advanced or metastatic IMFT deemed incurable with surgery, radiotherapy, or systemic therapy; measurable disease; an Eastern Cooperative Oncology Group performance status of 0-2; and adequate haematological, renal, and liver function. Central reference pathology was done for confirmation of the diagnosis, and ALK positivity or negativity was assessed centrally using immunohistochemistry and fluorescence in-situ hybridisation based on archival tumour tissue and defined as ALK immunopositivity or rearrangements in at least 15% of tumour cells. Eligible ALK-positive and ALK-negative patients received oral crizotinib 250 mg twice per day administered on a continuous daily dosing schedule (the duration of each treatment cycle was 21 days) until documented disease progression, unacceptable toxicity, or patient refusal. If at least two of the first 12 eligible and assessable ALK-positive patients achieved a confirmed complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, a maximum of 35 patients were to be enrolled. If at least six ALK-positive patients achieved a confirmed response, the trial would be deemed successful. The primary endpoint was the proportion of patients who achieved an objective response (ie, a complete or partial response) as per RECIST 1.1, with response confirmation assessed by the local investigator every other cycle. Activity and safety endpoints were analysed in the per-protocol population. This trial is registered with ClinicalTrials.gov, number NCT01524926. FINDINGS: Between Oct 3, 2012, and April 12, 2017, we recruited and treated 20 eligible participants, 19 of whom were assessable for the primary endpoint. Median follow-up was 863 days (IQR 358-1304). Six of 12 ALK-positive patients (50%, 95% CI 21·1-78·9) and one of seven ALK-negative patients (14%, 0·0-57·9) achieved an objective response. The most common treatment-related adverse events in the 20 participants were nausea (11 [55%]), fatigue (9 [45%]), blurred vision (nine [45%]), vomiting (seven [35%]), and diarrhoea (seven [35%]). Eight serious adverse events occurred in five patients: pneumonia, fever of unknown cause, a heart attack with increased creatinine and possible sepsis, an abdominal abscess with acute renal insufficiency, and a QT prolongation. INTERPRETATION: With 50% of participants with ALK-positive tumours achieving an objective response, crizotinib met the prespecified criteria for success in this trial. The results presented here support the rationale for inhibiting ALK in patients with IMFT. Crizotinib could be considered as the standard of care for patients with locally advanced or metastatic ALK-positive IMFT who do not qualify for curative surgery. FUNDING: The European Organisation for Research and Treatment of Cancer and Pfizer.
Asunto(s)
Quinasa de Linfoma Anaplásico/genética , Antineoplásicos/administración & dosificación , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Crizotinib/administración & dosificación , Neoplasias Pulmonares/tratamiento farmacológico , Miofibroma/tratamiento farmacológico , Adulto , Anciano , Quinasa de Linfoma Anaplásico/efectos de los fármacos , Carcinoma de Pulmón de Células no Pequeñas/genética , Progresión de la Enfermedad , Resistencia a Antineoplásicos/genética , Europa (Continente) , Femenino , Reordenamiento Génico/genética , Humanos , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Miofibroma/genética , Ensayos Clínicos Controlados no Aleatorios como Asunto , Estudios Prospectivos , Criterios de Evaluación de Respuesta en Tumores Sólidos , Resultado del TratamientoAsunto(s)
Miofibroma/diagnóstico , Granuloma de Células Plasmáticas del Pulmón/diagnóstico , Corticoesteroides/uso terapéutico , Adulto , Secuestro Broncopulmonar/diagnóstico , Calcinosis/diagnóstico por imagen , Calcinosis/etiología , Tumor Carcinoide/diagnóstico , Carcinoma/diagnóstico , Terapia Combinada , Diagnóstico Diferencial , Humanos , Inflamación , Neoplasias Pulmonares/diagnóstico , Masculino , Persona de Mediana Edad , Miofibroma/tratamiento farmacológico , Miofibroma/secundario , Miofibroma/cirugía , Granuloma de Células Plasmáticas del Pulmón/tratamiento farmacológico , Granuloma de Células Plasmáticas del Pulmón/cirugía , Neumonectomía , Neumonía/etiología , Recurrencia , Tomografía Computarizada por Rayos XRESUMEN
Infantile myofibromatosis is an uncommon and benign condition presenting in the neonatal period. It is self-limiting disease that may present as a localised or generalised process. Various examples of this entity have been reported in the literature. This report describes a neonate with a rapidly growing oropharyngeal lesion obstructing the airway that had the typical histological features of an infantile myofibroma. This case report highlights that a solitary myofibroma may be incredibly extensive making complete excision impossible and can be particularly challenging to manage in terms of airway stabilisation.